CN110693914A - Application of vaccinia virus inflammation-causing rabbit skin extract in treatment of rheumatoid arthritis - Google Patents
Application of vaccinia virus inflammation-causing rabbit skin extract in treatment of rheumatoid arthritis Download PDFInfo
- Publication number
- CN110693914A CN110693914A CN201911028327.9A CN201911028327A CN110693914A CN 110693914 A CN110693914 A CN 110693914A CN 201911028327 A CN201911028327 A CN 201911028327A CN 110693914 A CN110693914 A CN 110693914A
- Authority
- CN
- China
- Prior art keywords
- rheumatoid arthritis
- vaccinia virus
- treatment
- skin extract
- rabbit skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
Abstract
The invention relates to an application of a vaccinia virus inflammation-causing rabbit skin extract in treatment of rheumatoid arthritis, wherein the effective dose of the vaccinia virus inflammation-causing rabbit skin extract is 0.3-1 u/kg. The invention has the advantages that: the vaccinia virus inflammation-causing rabbit skin extract has a remarkable treatment effect on an animal model with rheumatoid arthritis through a rheumatoid arthritis treatment medicine, and can achieve higher drug effect through smaller administration volume and administration dosage.
Description
Technical Field
The invention relates to treatment of rheumatoid arthritis, in particular to application of a vaccinia virus inflammation-causing rabbit skin extract in treatment of rheumatoid arthritis.
Background
Rheumatoid Arthritis (RA) is a chronic, inflammatory synovitis-predominant systemic disease of unknown etiology. It is characterized by multiple joints, symmetry and invasive arthritis of small joints of hands and feet, and joint deformity and function loss caused by the fact that the external organs of joints are affected by serum rheumatoid factor positivity.
The term "vaccinia virus inflammatory rabbit skin extract" as used herein refers to an active substance extracted from the skin of a rabbit inflamed by vaccinia virus, as described in chinese patent ZL98103220.6, which is incorporated herein by reference in its entirety. The variola extract is commercially available under the trade name of "ready-to-use" and is produced by the limited Sagao company of the West pharmacy. Furthermore, extracts from vaccinia virus-causing rabbit skin were also studied and discussed in the following applications: chinese patent application 99123485.5 filed on 12/11/1999, chinese patent application 96123286.2 filed on 19/12/1996 and chinese patent application 98103914.6 filed on 07/1/1998. However, immediate adaptation has not been reported for rheumatoid arthritis treatment.
The present inventors have studied this and found that this has a favorable effect on experimental rheumatoid arthritis treatment in animal models.
Disclosure of Invention
The invention aims to solve the technical problem of providing an application of an extract of variola pox virus inflammation-causing rabbit fur in the treatment of rheumatoid arthritis so as to solve the problems in the prior art.
In order to solve the technical problems, the technical scheme of the invention is as follows: the application of the vaccinia virus inflammation-causing rabbit skin extract in treating rheumatoid arthritis has the innovation points that: the effective dose of the vaccinia virus inflammatory rabbit skin extract is 0.3-1 u/kg.
The invention has the advantages that: the vaccinia virus inflammation-causing rabbit skin extract has a remarkable treatment effect on an animal model with rheumatoid arthritis through a rheumatoid arthritis treatment medicine, and can achieve higher drug effect through smaller administration volume and administration dosage.
Detailed Description
The following examples are presented to enable one of ordinary skill in the art to more fully understand the present invention and are not intended to limit the scope of the embodiments described herein.
Examples
1. Drugs and reagents
Ready-to-use injection, size 10u/ml, 25 ml/bottle (available from West pharmacy, Rugao, Inc.); normal saline with the concentration of 0.9%; dexamethasone was used at a concentration of 0.5 mg/kg-1.
2. Laboratory animal and model making
DBA/1 mice with the body mass of 20-24 g and the age of 8 weeks are selected for male breeding in SPF grade. According to the general standard method, mice are induced by type II collagen to prepare a rheumatoid arthritis (CIA) model, and typical symptoms begin to appear 3-4 weeks after induction.
3. Animal grouping and dosing regimens
The experimental groups included: three different dose groups of a normal control group, a model group, a positive control group (dexamethasone 0.5 mg.kg < -1 >) and a test drug group (low dose is 0.3u/kg, medium dose is 0.6u/kg and high dose is 1 u/kg), and 10 drugs are respectively used in each group. See table 1 for details.
TABLE 1 Experimental animal groups and dosing regimens
4. Clinical index
4.1 weight change: mice were weighed (average weight per one per group) 1 time every six days and the results recorded are shown in table 2.
TABLE 2 grouping of experimental animals and body weight recording results
4.2 sole thickness: caliper measurements (average sole thickness per group) were taken 1 time every six days and the results are reported in Table 3.
TABLE 3 grouping of experimental animals and results of foot sole thickness
4.3 clinical score: the scoring criteria were as follows: 0 minute: the joint is normal; 1 minute: slight red swelling of the joints; and 2, dividing: the red and swollen joints are serious and involve the whole joints; and 3, dividing: dysfunction of the paw or joint, joint stiffness. The total score for joint inflammation was the sum of the four limb scores for each mouse, with the highest score of 12 for each mouse. If the total joint score is not more than 1, the mouse model is successfully made.
TABLE 4 Effect of extendibility on clinical Scoring in laboratory animals
5. Histopathological observation
At the end of the observation of the D60 experiment, the mice were sacrificed, the ankle joints were taken for histological sectioning, HE staining, and the histopathological changes including inflammatory cell infiltration of joint tissues and bone destruction were observed under a microscope.
TABLE 5 Effect of extemporaneous adaptation on histopathology of Experimental animals
The vaccinia virus inflammation-causing rabbit skin extract is obtained through tests, has a remarkable treatment effect on an animal model of rheumatoid arthritis through a rheumatoid arthritis treatment medicine, can achieve higher drug effect through smaller administration volume and administration dosage, and is suitable for treating the rheumatoid arthritis at a proper dosage of 0.6-1 u/kg.
The foregoing shows and describes the general principles and features of the present invention, together with the advantages thereof. It will be understood by those skilled in the art that the present invention is not limited to the embodiments described above, which are described in the specification and illustrated only to illustrate the principle of the present invention, but that various changes and modifications may be made therein without departing from the spirit and scope of the present invention, which fall within the scope of the invention as claimed. The scope of the invention is defined by the appended claims and equivalents thereof.
Claims (1)
1. The application of the vaccinia virus inflammation-causing rabbit skin extract in treating rheumatoid arthritis is characterized in that: the effective dose of the vaccinia virus inflammatory rabbit skin extract is 0.3-1 u/kg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911028327.9A CN110693914A (en) | 2019-10-28 | 2019-10-28 | Application of vaccinia virus inflammation-causing rabbit skin extract in treatment of rheumatoid arthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911028327.9A CN110693914A (en) | 2019-10-28 | 2019-10-28 | Application of vaccinia virus inflammation-causing rabbit skin extract in treatment of rheumatoid arthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110693914A true CN110693914A (en) | 2020-01-17 |
Family
ID=69202410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911028327.9A Pending CN110693914A (en) | 2019-10-28 | 2019-10-28 | Application of vaccinia virus inflammation-causing rabbit skin extract in treatment of rheumatoid arthritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110693914A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111904981A (en) * | 2020-09-07 | 2020-11-10 | 威世药业（如皋）有限公司 | Production method of variola pox virus inflammation-causing rabbit fur |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1613305A (en) * | 2004-12-06 | 2005-05-11 | 威世药业（如皋）有限公司 | Cony fur containing biological active substances and use thereof |
| CN101732348A (en) * | 2008-11-11 | 2010-06-16 | 威世药业（如皋）有限公司 | Application of varicella vaccine inflammation induced rabbit fur extractive in preparing medicaments for treating acute cerebrovascular diseases |
| CN111904981A (en) * | 2020-09-07 | 2020-11-10 | 威世药业（如皋）有限公司 | Production method of variola pox virus inflammation-causing rabbit fur |
-
2019
- 2019-10-28 CN CN201911028327.9A patent/CN110693914A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1613305A (en) * | 2004-12-06 | 2005-05-11 | 威世药业（如皋）有限公司 | Cony fur containing biological active substances and use thereof |
| CN101732348A (en) * | 2008-11-11 | 2010-06-16 | 威世药业（如皋）有限公司 | Application of varicella vaccine inflammation induced rabbit fur extractive in preparing medicaments for treating acute cerebrovascular diseases |
| CN111904981A (en) * | 2020-09-07 | 2020-11-10 | 威世药业（如皋）有限公司 | Production method of variola pox virus inflammation-causing rabbit fur |
Non-Patent Citations (2)
| Title |
|---|
| 潘云峰等: "牛痘疫苗致炎兔皮提取物注射液对类风湿关节炎关节疼痛的疗效观察", 《中国现代医药杂志》 * |
| 闫斌等: "牛痘疫苗致炎兔皮提取物穴位注射治疗类风湿性关节炎的疗效观察", 《医学临床研究》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111904981A (en) * | 2020-09-07 | 2020-11-10 | 威世药业（如皋）有限公司 | Production method of variola pox virus inflammation-causing rabbit fur |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yuan et al. | Effects of preventive Administration of Juanbi Capsules on TNF-α IL-1 and IL-6 contents of joint fluid in the rabbit with knee osteoarthritis | |
| CN104546992A (en) | Folium cortex eucommiae extract as well as preparation method and application thereof | |
| Wu et al. | An herbal formula attenuates collagen-induced arthritis via inhibition of JAK2-STAT3 signaling and regulation of Th17 cells in mice | |
| Wu et al. | Effect and mechanism of Qingfei Paidu decoction in the management of pulmonary fibrosis and COVID-19 | |
| WO2006026926A1 (en) | A medicinal composition for treating hepatic fibrosis and its preparation | |
| Francescato et al. | Treatment with a p38 MAPK inhibitor attenuates cisplatin nephrotoxicity starting after the beginning of renal damage | |
| CN110693914A (en) | Application of vaccinia virus inflammation-causing rabbit skin extract in treatment of rheumatoid arthritis | |
| CN108853501B (en) | Application of magnetosensitive protein in improving neurodegenerative diseases | |
| CN112138146A (en) | Application of MANF protein | |
| CN101095743B (en) | Exterior-applied medicine composition for treating gynecologic diseases and method of making the same and the use thereof | |
| CN110123868B (en) | Application of scorpion-containing traditional Chinese medicine composition in preparation of medicine for treating rheumatoid arthritis bone erosion | |
| CN113908149A (en) | Application of formononetin in preparation of medicine for preventing and treating acute lung injury | |
| Zeng et al. | Effects of Jiawei Shaoyao‐Gancao Decoction and its drug‐containing serum on proliferation, apoptosis, and ultrastructure of human adenomyosis foci cells | |
| CN105213405A (en) | Dihydrotanshinone I is preparing the application in anti-hepatic fibrosis medicines | |
| CN106619602B (en) | The purposes of leonurine | |
| CN101554386A (en) | Medicine composition for curing hepatic disease and preparation method thereof | |
| Cao et al. | Protective effects of Wusen Erlian granules in experimental model of viral myocarditis | |
| CN107802632B (en) | Traditional Chinese medicine effective component composition for treating rheumatic arthritis and rheumatoid arthritis and application thereof | |
| Ouyang et al. | Role of autophagy in liver fibrosis with qi deficiency and blood stasis via the Nrf2-Keap1-Are signaling pathway | |
| CN104666319B (en) | Rhodioside is preparing the application in treating gout medicine | |
| CN114159435B (en) | Application of Fuziling in preparing medicine for treating arthritis | |
| CN105998451B (en) | Rhizoma alismatis acetic acid ethyl ester extract and preparation method thereof and the application in End-stage renal disease medicine is prepared | |
| CN117357508B (en) | Application of ciliristat in preparation of medicine for treating primary cholangitis | |
| CN102600376B (en) | Application of Gastrodia Elata Bl. and extract of Gastrodia Elata Bl. in preparation of medicine for treating and repairing peripheral nerve injury | |
| CN106728836B (en) | Traditional Chinese medicine composition for treating infantile viral myocarditis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200117 |